CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. CohBar has assembled a leading position in exploring the mitochondrial genome and its utility for the development of novel therapeutics, including world-renowned expertise in mitochondrial biology, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar is utilizing its Mito+ platform to identify and develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis. CohBar is planning to file an IND for its second clinical candidate CB5138-3 in the second half of 2023, with an initial indication of idiopathic pulmonary fibrosis. The company has previously demonstrated clinical proof of concept for its approach with the positive topline data from its CB4211 product candidate being developed for NASH and obesity.
Company profile
Ticker
CWBR
Exchange
Website
CEO
Steven B. Engle
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cohbar, Inc.
SEC CIK
CWBR stock data
Latest filings (excl ownership)
8-K
Other Events
7 Dec 22
8-K
Other Events
17 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
CohBar Reports Third Quarter 2022
8 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
22 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
CohBar Reports Second Quarter 2022
15 Aug 22
8-K
Departure of Directors or Certain Officers
12 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
DEFA14A
Additional proxy soliciting materials
24 May 22
Transcripts
CWBR
Earnings call transcript
2022 Q3
11 Nov 22
CWBR
Earnings call transcript
2022 Q2
16 Aug 22
CWBR
Earnings call transcript
2022 Q1
17 May 22
CWBR
Earnings call transcript
2021 Q4
30 Mar 22
CWBR
Earnings call transcript
2021 Q3
16 Nov 21
CWBR
Earnings call transcript
2021 Q2
11 Aug 21
CWBR
Earnings call transcript
2021 Q1
18 May 21
CWBR
Earnings call transcript
2020 Q4
31 Mar 21
CWBR
Earnings call transcript
2020 Q3
17 Nov 20
CWBR
Earnings call transcript
2020 Q2
13 Aug 20
Latest ownership filings
4
Jeffrey Francis Biunno
3 Aug 22
4
Joseph J. Sarret
3 Aug 22
4
Stephanie Tozzo
12 Jul 22
3
Stephanie Tozzo
12 Jul 22
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G/A
Cohen Pinchas
1 Feb 22
SC 13G/A
Barzilai Nir Yacov
1 Feb 22
4
Jeffrey Francis Biunno
3 Jan 22
4
Joseph J. Sarret
3 Jan 22
SC 13G
CVI Investments, Inc.
8 Nov 21
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.21 mm | 4.21 mm | 4.21 mm | 4.21 mm | 4.21 mm | 4.21 mm |
| Cash burn (monthly) | (no burn) | 414.09 k | 823.60 k | 937.28 k | 596.21 k | 869.42 k |
| Cash used (since last report) | n/a | 1.69 mm | 3.36 mm | 3.82 mm | 2.43 mm | 3.55 mm |
| Cash remaining | n/a | 2.52 mm | 852.37 k | 388.76 k | 1.78 mm | 665.50 k |
| Runway (months of cash) | n/a | 6.1 | 1.0 | 0.4 | 3.0 | 0.8 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 17 |
| Opened positions | 0 |
| Closed positions | 23 |
| Increased positions | 0 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 585.00 k |
| Total shares | 4.72 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 4.52 mm | $0.00 |
| Vanguard | 63.00 k | $181.00 k |
| Optimum Investment Advisors | 50.82 k | $146.00 k |
| Renaissance Technologies | 21.12 k | $61.00 k |
| Two Sigma Investments | 18.42 k | $53.00 k |
| Two Sigma Advisers | 17.89 k | $52.00 k |
| Geode Capital Management | 15.52 k | $44.00 k |
| BLK Blackrock | 8.55 k | $25.00 k |
| Tower Research Capital | 3.06 k | $9.00 k |
| MS Morgan Stanley | 1.27 k | $4.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Aug 22 | Jeffrey Francis Biunno | Common Stock | Grant | Acquire A | No | No | 0.1488 | 26,203 | 3.90 k | 57,355 |
| 1 Aug 22 | Joseph J. Sarret | Common Stock | Grant | Acquire A | No | No | 0.1488 | 131,017 | 19.50 k | 151,017 |
| 11 Jul 22 | Stephanie Tozzo | Stock Option Common Stock | Grant | Acquire A | No | No | 0.197 | 200,000 | 39.40 k | 200,000 |
| 29 Dec 21 | Jeffrey Francis Biunno | Stock Option Common Stock | Grant | Acquire A | No | No | 0.34 | 75,000 | 25.50 k | 75,000 |